Overview

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Status:
RECRUITING
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Phase:
PHASE2
Details
Lead Sponsor:
Tyra Biosciences, Inc